Avanir Pharmaceuticals, Inc. (AVNR) Reports In-Line Q4 EPS Loss of $0.14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Financial Fact:
Total operating expenses: 40.52M
Today's EPS Names:
BELFB, GFL, NHTC, More
Financial Fact:
Total operating expenses: 40.52M
Today's EPS Names:
BELFB, GFL, NHTC, More
Join SI Premium – FREE
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $4.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plexus Corp (PLXS) Tops Q4 EPS by 29c; offers guidance
- Wex, Inc. (WEX) Tops Q3 EPS by 48c; offers guidance
- Cactus, Inc. (WHD) Tops Q3 EPS by 19c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
